July 23, 2023

Dr. Helen Torley - President and CEO of Halozyme

In this episode of Life Science Success, my guest is Dr. Helen Torley. Dr. Torley is the President and CEO of Halozyme. Halozyme's innovative and disruptive solutions provide new therapeutic options that could significantly improve the patient...

Show Notes
Guest Profile

Dr. Helen Torley, CEO of Halozyme, discusses the company's dedication to improving patient experiences and outcomes through their research and development of monoclonal antibodies and small molecules.
Halozyme places a strong emphasis on corporate culture, including cross-functional collaboration and community outreach.
Dr. Torley shares how the book "The Five Dysfunctions of a Team" has influenced her leadership style.
Dr. Torley is inspired by the innovative ideas and enthusiasm of her team members.
She expresses concern about the impact of remote work on creativity, problem-solving, and personal development.
The company is focused on putting patients at the center of their mission.
They have a strong focus on community outreach, with 70% employee participation in volunteering events.
She shares a personal story about a family member's experience with cancer treatment to underscore the importance of improving patient experiences.
This episode of the Life Science Success podcast provides insight into the innovative solutions Halozyme is developing and their commitment to patient-centered care.

Please check out our Life Science Success Resources. You will find tools that will support growing companies and books for authors I have interviewed.

Dr. Helen Torely, CEO of Halozyme, M.B. Ch. B., M.R.C.P.

CEO

Helen Torley
M.B. Ch. B., M.R.C.P.
President and Chief Executive Officer

Dr. Helen Torley is the President and CEO of Halozyme. Halozyme's innovative and disruptive solutions provide new therapeutic options that could significantly improve the patient experience. Halozyme changes how treatments are delivered. When using Halozyme’s ENHANZE drug-delivery technology, the treatment time for a drug to treat the most common form of blood cancer is cut from a four to six hours IV infusion to an approximately 5-minute subcutaneous delivery.

Dr. Torley brings extensive commercial and business experience as well as an extensive knowledge of the biotechnology industry. Dr. Torley joined Halozyme in January 2014 as President and Chief Executive Officer. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis®, Prolia®, Sensipar®, and Miacalcin®. Prior to joining Halozyme, Dr. Torley served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals (Onyx) from August 2011 to December 2013. In this role she was responsible for the successful launch of Kyprolis in the US and led the development of Onyx’s commercial capabilities in ex-U.S. markets and in particular, in Europe. She also oversaw the development and commercial collaboration with Bayer on Nexavar® and Stivarga®.

Prior to Onyx, Dr. Torley spent 10 years in management positions at Amgen Inc., most recently serving as Vice President and General Manager of the U.S. Bone Health Business Unit from 2009 to 2011 and the U.S. Nephrol… Read More